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ABSTRACT
Alzheimer’s disease (AD), the most prevalent neurodegenerative disease, is
characterized in part by disruptions in axonal transport. Axonal transport is a process by
which motor proteins carry organelles and other cargo made in the neuronal cell body
along microtubule tracks to distal regions of the axon. The microtubule-associated protein
(MAP) Tau plays a crucial role in regulating axonal transport, and is implicated in the
development of AD and other types of dementia collectively known as Tauopathies. Tau
is a neuronal-specific MAP that has six isoforms alternatively spliced from a single gene.
These isoforms differ by the presence of zero, one, or two N-terminal acidic inserts and
three or four C-terminal microtubule binding repeats. Tau is also known to be an
intrinsically disordered protein that undergoes a dynamic equilibrium between static and
diffusive states on the microtubule surface. The dynamics of Tau are important in the
regulation of motor protein mediated axonal transport in neurons. Isoform-specific
differences in the dynamic behavior of Tau on the microtubule surface, however, are not
yet fully understood. Diffusive Tau is thought to be stabilized by electrostatic interactions
between its N- and C-termini while static Tau is proposed to be extended with its Cterminal repeats contacting the microtubule and the N-terminus projected away from the
microtubule surface. Thus, the N-terminal inserts may help regulate Tau’s dynamic
behavior and function during axonal transport. In this study, the dynamics of two
different isoforms of Tau, both with three-microtubule binding repeats but a different
number of N-terminal acidic inserts, were assessed using single molecule imaging
techniques and novel data analysis methods.
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LITERATURE REVIEW
Overview
This literature review will address from global to the molecular the role of the protein
Tau in the developed adult brain. The work will begin with a look at the gross features of
Alzheimer’s disease (AD), some of the known pathological features of AD, and then look
at proposed molecular causes. One of these proposed molecules involved in AD is the
protein Tau. The literature review will therefore look at what is known about the structure
and function of Tau and its known roles in the neurons. One of these is Tau’s influence
on axonal transport and how that process is disrupted in AD. The review will then
introduce how Tau’s role in axonal transport is related to its dynamics behavior on the
microtubule surface. The current understanding is that Tau binds to microtubules in both
diffusive and static state but little is currently know about differences in dynamic
behavior among different isoforms of Tau. This study examines the differences in
dynamics of two Tau isoforms, 3RS and 3RL. In addition, this research will look at
previous work and limitations of the previous data analysis methods used. The current
research will introduce a novel data analysis method designed to eliminate subjectivity
and be more sensitive to short time-scale events. Overall, the literature review will look at
the pathological features in AD to the physiological processes. This will highlight the
need to better understand the Tau proteins function and its role in neurodegeneration.
Alzheimer’s disease is a devastating type of neurodegeneration.
Alzheimer's disease (AD) is one of the most common types of dementia affecting
approximately 5.4 million people in the United States1, yet an estimated half of cases go
undiagnosed2. Since a decrease in cognitive function is normal with aging, distinguishing
1

the transition from normal cognitive decline to mild cognitive impairment (MCI) to AD
must occur with coordination by the patient, caregivers, and health care providers.
Patients are often seen in clinics or elsewhere where cognitive decline is a secondary or
tertiary concern3. Health care providers must, therefore, recognize early symptoms of AD
for close monitoring.
Although important to recognize, an early diagnosis does not necessarily correlate
with a longer lifespan or quality of life in those affected. Lifespans and death rates from
AD remain difficult to categorize since patients often have a primary cause of death other
than AD. The cause of death may be directly or indirectly related to the person’s
cognitive decline and losses in activities of daily living (ADL). These include
susceptibility to infection, depression, or muscle atrophy if a patient becomes bedridden.
Estimates for 2016 predicted that over 700,000 people in the United States would die that
year with AD1. Reporting standards still may not be capturing all AD-related deaths,
particularly if a case was not diagnosed ante-mortem.
The prevalence of AD has grown rapidly over the past hundred years since Dr.
Alois Alzheimer first described the disease in 1906. This is partly an artificial increase as
more education on the disease has led to more screens in at-risk patients. The numbers of
deaths from the disease have therefore risen because of the increase in people in the
United States diagnosed with AD. In addition, since studies have shown a greater risk of
developing AD with increasing age4, the rates of AD will continue to increase as life
expectancies increase. In the 2016 statistics for the United States, 44 percent of those
with AD were aged 75 to 84, and 37 percent were 85 or older1. The majority of people in
the United States with AD are, therefore, above 75 years old due in part to longer life
2

expectancies and better diagnostics.
With these rising rates of AD, it is imperative to understand how the disease state
differs from typical aging patterns. According to the 2013 APA guidelines, a patient can
receive an AD diagnosis if their symptoms involve a loss of one of the following:
coherent speech, spoken or written language comprehension, object identification, basic
motor skills, abstract thinking, or multi-command tasks. The presence of these symptoms
must be medically verified and occur along with a memory decline and, critically, disrupt
capable daily living5. These guidelines will help standardize diagnosis of AD by health
care providers but must be complemented with a better understanding of underlying
molecular mechanisms, disease markers, and diagnostic tools.
Pathological Features of Alzheimer's disease
The APA guidelines are a useful but not complete criterion for an AD diagnosis.
Medical imaging techniques have become more advanced, thereby increasing AD
detection sensitivity. They are limited though because the disease is not isolated to a
discrete part of the brain. Much is still not understood about the tissue atrophy seen in the
brain in AD. Current research in the field has not come to a complete consensus about the
sites of initial degeneration and whether the atrophy seen in different brain regions is
connected or develops independently. What is known is that there are common patterns
of atrophy in regions of the brain that include, with overlap; the limbic system, medial
temporal lobe, frontal temporal lobe, and hippocampus (Figure 1).
One confirmed pathology is that the atrophy seen throughout the brain originates
from massive cell death of neurons, the primary cell of the nervous system (Figure 2).
These neurons are responsible for signaling, cognition, and motor coordination. Neurons
3

have several defining features including the cell body, known as the soma, with multiple
projections radiating off of the soma. These projections are differentiated into dendrites
and axons. The dendrites are smaller and more numerous projections that receive the
signals. The signaling is then propagated through the longer extensions known as axons.
Most axons extend several microns away from the soma although, in extreme cases,
axons can extend up to one meter. The range of dendrite compositions, axons, and their
lengths correlates with the diversity of functions required by neurons found in both the
central nervous system (CNS) and peripheral nervous system (PNS).
Within these regions there are gray matter (GM) and white matter (WM)
atrophies. The GM atrophies are from degeneration of the cell bodies or soma of central
nervous system (CNS) neurons, while WM atrophies are degeneration of the CNS axons.
Both atrophies are present in AD but it is not clear if the observed degenerations are
connected, dependent, or entirely independent from each other6. Different studies have
contradictory results with finding ranging from AD as a GM disease with WM atrophy a
secondary effect to other studies showing no long-term connection3. Another hypothesis
suggests that WM degeneration precedes GM atrophy7. The difference may be region
specific as some correlation of GM and WM atrophy is seen in the hippocampus6 but
there is little connection in the entorhinal cortex8. This field needs more study to
understand the interplay between different brain regions and specific patterns of
neurodegeneration present.
In addition to atrophies in different regions of the brain occurring in afflicted
individuals, AD patients exhibit different levels of global neurodegeneration and
reduction in brain volumes. The necrosis in AD is not entirely generalizable but some
4

common features have been observed. Globally there is an average 15% reduction of
hippocampal volume per year in patients with AD compared to a 1.5% reduction in agecorrelated cognitively-normal individuals9. In addition, 80-90% of AD patients have
medial temporal lobe atrophy (MTA) on both the hippocampus and entorhinal cortex
(Figure 1)2.
While research in Alzheimer's disease has increased exponentially since the time
of Dr. Alois Alzheimer and Dr. Emil Kraeplin in 1906, there is still relatively little
understood

about

this

devastating

disease.

The

underlying

causes

of

the

neurodegeneration are multidimensional and it is not clear how changes on the molecular
level translate into the observed neurodegeneration. Within neurons several molecular
factors are implicated in AD, but not entirely understood. The transition from healthy
neurons to diseased ones is unclear but understanding the molecular markers is important
for early detection and identifying therapeutic targets.
Tau is implicated in Alzheimer’s disease.
The gross atrophies seen in the brain have a biochemical commonality as two
macromolecules have been shown to aggregate in neurons of the medial temporal lobe
(MTL). These molecules are thought to disrupt neuronal functions and lead to atrophy.
With the advances in brain scan technology, several distinctive tangles and plaques have
been found in patients diagnosed with AD. The tangles, known as neurofibrilary tangles
(NFTs), are composed of the protein Tau and the plaques are composed of the amyloid-β
protein fragment. The NFTs are found deposited in the MTL in the hippocampus and
entorhinal cortex2. The pathological accumulation of these molecules contributes to the
massive neuronal death seen in AD. Even though the exact roles of Tau and amyloid-β
5

are not well known, their pathological presence is well confirmed.
The Tau protein is implicated in a broader range of diseases that are classified as
Tauopathies. These diseases include AD as well as frontal temporal lobe dementia, some
types of Parkinson’s disease, and Progressive supranuclear palsy. The Tau protein, which
functions predominately in axons, is part of a class of microtubule associated proteins
(MAPs)10. Tau has some known functions in the neurons but there is not much known
about Tau’s dynamics or structure in the neuron and how this determines its functions or
role in Tauopathies.
Tau contains an N-terminal projection domain that contributes to its different
proposed functions.
Tau is a MAP found predominately in the axon associated with microtubules. It
has a dynamic structure and does not have a known secondary structure11. The structure
of Tau is important to understand in order to fully comprehend its functions in developed
neurons. The N-terminus of Tau (Figure 3) is a projection domain that does not associate
with the microtubule12, and is important for proposed functions of Tau. These include a
role in signaling pathways and in microtubule dynamics and stability13 (Figure 4).
Initial work showed that the N-terminus of Tau was important in determining
microtubule spacing in microtubule bundles within the axon. Microtubules within
bundles are closer to each other in the presence of Tau than with other MAPs or the
absence of Tau. The N-termini of MAPs may interact with each other on adjacent
microtubules to determine spacing as a function of their own length and reach. The in
vitro study found that the microtubule spacing with Tau is consistent with spacing of
microtubules in bundles found in actual axons14. Tau has a shorter N-terminal projection
6

domain than the MAPs found in dendrites, suggesting that microtubules in axon bundles
are closer together than in dendrites.
In addition, the N-terminal projection domain has been shown to facilitate cargo
delivery in the axon. Previous work has additionally shown that a region of amino acids
from 2-18, known as a phosphatase-activating domain (PAD), is the necessary and
sufficient region for cargo delivery15. This PAD is found in all Tau molecules and
different charges on the PAD have been shown recently to have effects on the dynamics
of Tau16.
The projection domain of Tau has additional effects on microtubule stability as
displayed indirectly by N-terminal truncations. When the N-terminus is truncated in vitro,
mimicking a species found pathologically in NFTs of AD brains, there is more Tau
associated with tubulin. The truncated Tau is specifically associated more with acetylated
tubulin and detyrosination tubulin. The detyrosinated tubulin species is a marker of
microtubule stability since the PTMs occur on stable and long-lasting microtubules17. Tau
is additionally known to interact with histone deacetylase 6 (HDAC6), the tubulin
deacetylase, to prevent the deacetylase activity18. Although Tau plays an important role in
HDAC6 activity, in vitro work with N-terminal truncations of Tau did not find an
increase in activity of HDAC6 in those samples17. The proposed loss-of-function of Tau
in inhibiting HDAC6 is potentially overcome by an increase in microtubules and stability
in the presence of truncated Tau. To understand the contradiction of more acetylation in
the presence of N-terminally truncated Tau, further work needs to determine if the
increased tubulin modifications in the presence of N-terminally truncated Tau is the result
of increased stability because Tau is more tightly bound without its N-terminus.
7

The Tau protein has six isoforms with common domains between the isoforms.
The gene locus for Tau on chromosome seventeen19 contains alternative splice
sites resulting in six predominant isoforms (Figure 3). The primary structure of all Tau
isoforms consists of an acidic N-terminus containing the PAD, two approximately central
proline-rich regions, and C-terminal microtubule-binding repeats (MTBRs) (Figure 3). In
the C-terminal region, isoforms of Tau either have 3 or 4 copies of a 31-amino acid
microtubule-binding repeat insert. At the N-terminal region of the protein after the PAD,
isoforms have 0, 1, or 2 copies of a 29-amino acid insert.
The six isoforms are named 3RS, 3RM, 3RL, 4RS, 4RM, and 4RL; reflecting the
combination of alternatively spliced inserts present in the protein. 3R versus 4R signifies
the presence of three or four microtubule binding repeats, while S (zero), M (one), or L
(two) refers to the number of acidic inserts in the N-terminal region of the molecule. The
longest isoform, 4RL, therefore contains four C-terminal microtubule-binding domains
and two N-terminal acidic inserts; while the shortest isoform, 3RS, contains three Cterminal microtubule-binding domains and no N-terminal acidic inserts20. In the adult
brain there is approximately a 1:1 expression of 3R to 4R isoforms21.
Tau converts between diffusive and static states on the microtubule.
Tau is a conformationally dynamic protein with no absolute secondary structure22.
This lack of secondary structure allows flexibility within the protein. It binds reversibly
with the microtubule through a combination of weak interactions in the MTBR, prolinerich regions, and inter-repeat regions between MTBRs23. The structure of Tau and the
presence of multiple isoforms, although not entirely understood, are thought to have
unique and overlapping roles in modulating different functions of Tau within the axon.
8

Despite no definite secondary structure, Tau has a proposed dynamic equilibrium
on the microtubule lattice switching between a static state and a diffusive state (Figure 5).
The longest and shortest isoforms, 3RS and 4RL, have different dynamic equilibriums in
in vitro studies. The 3RS isoform is found in the static state 62% of the time while 4RL is
static 49% of the time24. In general, the shorter isoform is more static than the longest
isoform. Previous to the research presented in this study, none of the other isoforms had
been characterized.
In single-molecule studies, 3RS has been found in the static state as individual
molecules as well as multi-protein complexes of two to three molecules in a ratio of 1:4:2
respectively. 4RL, however, prefers single molecule binding to two-molecule static
complexes in a 3:1 ratio24. The function of the multi-Tau complexes is not well
understood but there does not appear to be a significant number of molecules associated
together in the diffusive state.
Tau adopts some known features as it transitions into the disease state.
In the disease state all isoforms of Tau are dissociated from the microtubule and
prone to a pathological aggregation. The aggregates found in the disease state have
accumulated modifications and are different from the physiological and reversible multiTau complexes observed in single molecule studies. Pathologically Tau has been found
hyperphosphorylated, truncated, and associated into paired helical filaments (PHFs). Tau
is subjected to a caspase-3 and calpain cleavage at distinct sites creating several different
sized truncations that are found alongside full-length molecules in the PHFs17,25. The
PHFs are the initial component to forming NFTs that are no longer bound to the
microtubules and disrupt normal axon signaling26. In PHFs, Tau additionally has an
9

altered structure in the MTBRs that could contribute to aggregation27.
Proposed models for the conversion of Tau from physiological aggregates into
NFTs include stabilization of a bound state of Tau on the microtubule lattice24, post
translational modification like misregulated phosphorylation28, mutations throughout the
protein29, imbalance in the ratios between the isoforms expressed30, and other still
developing ideas. Since studies have shown that mRNA levels of Tau are consistent
between the healthy and disease states21, it does not appear that there is a change in the
amount of Tau present causing aggregation and PHFs. Further work is needed to discern
how microtubule binding is disrupted and the contribution of the different regions on
aggregation.
Pathologically Tau is proposed to disrupt axonal transport and communication
through the axon. Studies have suggested that since the PHFs and subsequent NFTs of
Tau are no longer bound to the microtubules they can disrupt normal axon signaling and
stability with the axon26. Since Tau is thought to have multiple roles in the axon, it is
difficult to chronicle the transition into the disease and Tau’s contribution.
Alzheimer’s disease is known to have disruptions in axonal transport.
Communication in a multicellular organism must be efficient yet accurate to
integrate the activities of differentiated cells ranging from small organisms to
coordinating the over two hundred distinct cell types in a human body. An organism must
sense both external and internal stimuli and elicit fast responses ranging from pain to
flight to hunger. Coordination of the senses occurs in the nervous system through its
defining cell type, the neuron.
In order to maintain viable cell environments for signal propagation, neurons must
10

constantly exchange ion channels, synaptic proteins, pre-synaptic vesicles, organelles
such as endosomes and mitochondria, plasma membrane components, and other
molecules between the axon and soma31. Two prevalent mechanisms exist for exchanging
molecules: simple diffusion and axonal transport32. Cytosolic, soluble proteins in
particular move through the axoplasm with a combination of these methods based on the
distance needed to travel and subcellular conditions34. Simple diffusion alone is not
sufficient to distribute proteins and other components down the length of the axon. Active
transport, therefore, is required for the mid- to long-range distance movement of cargo
along the length of the axon in both directions. The mechanism of axonal active transport
turns over elements of the axoplasm such as transporting the proteins that are primarily
synthesized in the soma to the distal axon (anterograde transport) and taking molecules
back to the soma for recycling (retrograde transport)33. In active transport motor proteins
capable of hydrolyzing ATP, known as ATPases, transport cargo like proteins and
organelles long distances along cytoskeletal filaments32.
In axons there are three main cytoskeleton polymers including actin and
neurofilaments, a type of intermediate filaments. The third type are microtubules and are
the major tracks for motor protein movement35. Microtubules are dynamic polymers that
provide structure and support for the axon as well as being tracks for motor proteins to
move along. Microtubules are composed of heterodimers of α- and β-tubulin that
associate and are added to both the plus-end of microtubules, the faster growing end
extending away from the soma, and the negative-end which grows more slowly towards
to soma. The tubulin heterodimers in a typical microtubule arrange into 13 protofilaments
creating a structure approximately 25 nm in diameter. The microtubules polymerize most
11

rapidly during neurogenesis in the growth cone of developing neurons and in mature
axons to develop short branch points off of stable microtubules populations. While the
microtubules undergo dynamic instability during these times, most of the microtubules in
the axon are strong, stable populations designated for structural support and as tracks for
motor protein movement36.
Within axons, different populations of stable microtubules can function in either a
structural role or as a main road for motor proteins. Microtubules in a more structural role
contain side extensions linking the microtubules to other cytoskeletal components like
actin and neurofilaments. These projections could inhibit motor protein transport and
axons have, therefore, evolved a separate population of microtubules for motor proteins
to use for transport37. The preference of motor proteins for certain microtubules is also
influenced by significant post-translational modifications (PTMs) on tubulin that
modulate motor protein transport, the motors ability to associate with the microtubule38,
and microtubule stability39. Tubulin is subjected to acetylation, polyglutamylation,
phosphorylation, and other forms of modification, particularly on its C-terminal tail. The
PTMs on tubulin’s C-terminal tail can influence the rate of motor protein transport as
well as the propensity of motor proteins to bind the microtubule38. Along with MAPs and
other proteins, these PTMs help regulate axonal transport and proper cargo delivery in the
axon.
Motor proteins such as kinesin transport cargo along microtubules.
Along the microtubules, molecular motors walk carrying membrane-bound
vesicles as their cargo. Members of the kinesin super family of motors (KIFs) are
primarily responsible for the anterograde motion, transporting cargo away from the cell
12

body (Figure 6), while cytoplasmic dynein primarily performs the anterograde motion
back towards the soma32. Dynein and some members of the kinesin family are processive,
meaning the motors can take multiple steps on the tubulin dimers of the microtubule
before dissociating. This processivity allows for greater run lengths along the microtubule
at a sufficient rate for cargo delivery to maintain the axonal environment.
The KIFs diversity of functions range from monomeric constructs to tetramers
with four heads performing roles other than cargo transport40. Certain motors within this
family are more attuned to carry particular cargos and navigate the motile environment
more easily31. Kinesin motors also have specific CNS and PNS functions, although there
is overlap between what cargos are carried by a particular kinesin and with how many
different kinesin types a particular cargo can associate40. Typically adaptor proteins are
involved linking KIFs or dynein with a designated cargo, increasing the combinations
and specificity available for motor transport41.
Multiple different motor proteins transport cargo in neurons and often multiple
motors are associated with the same cargo forming multi-motor complexes. The presence
of multiple motors on the same cargo is not entirely understood but is hypothesized to
help the motors navigate a complex axon environment crowded with other motors,
MAPs, actin, and additional factors42. In some cases there may be two oppositelydirected motors on a cargo, such as dynein and kinesin. This is also hypothesized to
ensure efficient cargo delivery as the dynein may engage causing the cargo to take a back
step around an obstacle. The anterograde-transported vesicle can then continue forward
as the kinesin motor has more space to find an available tubulin site43. Other cargos may
have multiple different kinesin family members on the same cargo or a combination of
13

KIFs and dynein42,44. The combination of different motors increases how far the cargo
travels on the crowded microtubule45.
Kinesin-1 motor proteins walk along microtubules decorated with proteins and
modifiers.
One of the most commonly found and studied kinesin motors in axonal transport
is kinesin-1. The kinesin-1 motor responsible for axonal transport contains two heavy
chains, forming the motor domains responsible for microtubule-binding and ATPase
activity, and two light chains able to bind membrane-bound vesicles and organelles32.
The kinesin-1 motors typically step on the β-tubulin of the microtubule lattice at
the interface between β-tubulin and the successive α-tubulin. The specificity for βtubulin lends kinesin-1 to take 8 nm steps per head in a 16 nm step cycle. In the absence
of crowding, kinesin ATPase activity follows Michaelis-Menten kinetics at a velocity of
600-800 nm/s, taking 12 ms per cycle at saturating ATP conditions.
Kinesin-1 hydrolyzes a single ATP per step in an ATP-cycle. In the cycle (Figure
6), the leading head is in the tightly bound state with no nucleotide in its binding site and
the trailing head has a bound ATP that is hydrolyzed. With the subsequent phosphate
release, the trailing head is in an ADP-bound state and has a weaker affinity for the
tubulin. The head will unbind from the tubulin and, as an ATP binds to the pocket in the
head that was initially the leading head, the neck linker docks and swings the trailing
head forward to the next β-tubulin. At the end of the cycle, the now leading head has no
nucleotide bound while the now trailing head has an ATP bound and is in a strong
binding state, causing the cycle to start over46. The ATP cycle relies on the two heads
being in different nucleotide states. This allows the motor to be processive because the
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trailing head can swing forward to find the next tubulin while the leading head is in a
strong-binding state.
The longest and shortest isoforms of Tau can differentially modulate kinesin-1
active transport in the axon.
The MAP Tau is one such obstacle that has the ability to inhibit kinesin-1 axonal
transport as it moves cargo towards the synapse47. Tau is proposed to inhibit kinesin-1 in
order to regulate the arrival of vesicles at the pre-synaptic membrane (Figure 7). Under
further study, 3RS and 4RL Tau cause kinesin-1 to pause or detach at different rates
(Figure 7A). In the presence of 3RS, kinesin-1 has a 50% reduced run length and was
more likely to detach than in the absence of Tau. Kinesin-1 in the presence of 4RL-Tau
show no change in run length but had a higher frequency of detachment compared to
microtubules without Tau47.
The different rates of kinesin-1 transport correlate with research on the dynamic
behavior of 3RS and 4RL isoforms on the microtubule surface (Figure 7A). Previous
studies have found that 3RS is in the static state 62% of the time. 4RL-Tau is more
dynamic and found in the static state 50% of the time. The differences in dynamic
equilibrium suggest that 3RS is more inhibitory of kinesin-1 due to its longer static
behavior.
Tau has additional roles in axonal transport.
In addition to modulating axonal transport, Tau is also involved in signaling
cascades for the delivery of kinesin-1 cargo at distinct sites along the axon. The signaling
cascade includes protein phosphatase 1 and GSK3β, a regulatory kinase. Truncations of
Tau lacking either the MTBRs or MTBRs and C-terminus had a similar effects on cargo
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deliver as full-length Tau by initiating the signaling cascade causing kinesin-1 to
dissociate from its cargo48. These results suggest that the N-terminus of Tau is sufficient
for inducing signaling cascades and regulation of axonal transport.
The signaling importance of Tau’s N-terminus has been further narrowed to a
phosphatase-activating domain (PAD) in all six isoform of Tau from amino acids 2-1815.
This PAD occurs before the start of the variable N-terminal acidic inserts. The PAD is
sufficient and necessary to initiate signaling for cargo deliver by kinesin-115, but is not
understood whether the presence of zero, one, or two acidic inserts has additional affects
on this cargo-delivery signaling cascade. Recent work has shown differential modulation
of kinesin-1 by the phosphorylation state of Tau. When the negative charge of a
phosphate is present at Tyrosine-18, the last amino acid of the PAD; the Tau molecule is
both more diffusive and less inhibitory of kinesin-116.
Tau does not have a known structure on the microtubule.
Since there is no confirmed structure of Tau’s conformation on the microtubule,
there is no clear understanding of how and why Tau transitions between the dynamic and
static states. In addition, it is not clear how Tau interacts with the tubulin heterodimers of
the microtubules. There are several cyro-EM studies suggesting that static Tau may lie on
the microtubules across multiple protofilaments49, along a single protofilament50, or with
density in between tubulin dimers51. Additional studies have also suggested that Tau
binds at the interface between α-tubulin and β-tubulin52,53. Due to Tau’s dynamic nature
and relatively quick transitions between static and diffusive states, however, the cryo-EM
studies have low resolution and other studies have not provided a conclusive structure of
static Tau.
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Despite a lack of convincing structure, there is strong evidence of how regions of
Tau contribute to its binding on the microtubule. Individual Tau regions have weak
microtubule binding capacities but with multiple regions interacting together, Tau has a
strong microtubule binding affinity. Through NMR spectroscopy studies, Tau’s Nterminus is found to have little interaction with the microtubule12. This is consistent with
research suggesting that the N-terminus of Tau is a projection domain that extends away
from the microtubule surface similar to those in other MAPs54. Other work has shown
that C-terminal truncations of Tau are diffuse and do not associate cleanly with
microtubules55, suggesting that the C-terminal MTBRs are necessary for microtubulebinding. In addition, Tau constructs with the MTBRs removed additionally are found
predominately in supernatant fractions in pelleting assays, indicating no detectable
microtubule-binding56.
Within 4RL-Tau there are six regions found to each have a weak binding affinity
to the microtubule. There is one region within each PRR, one each in microtubulebinding repeats one, two, and three; and one in the C-terminus of the protein. Together
these six regions are shown in NMR to shift and adopt a different structure upon
microtubule binding while other regions do not shift upon microtubule binding. The
inter-repeat regions of Tau, for example, remain unbound and structurally unchanged
upon microtubule binding, possibly contributing to Tau’s flexibility and reversible
binding on the microtubule surface12. There is a similar shift seen in sequences in 3RSTau with the exception of the region in the second MTBR as 3RS does not contain that
repeat-domain52.
Initial work on understanding regions within Tau found that the microtubule17

repeat domains of Tau, but not the C-terminus or N-terminus alone, bound to
microtubules in a pelleting assay. The pelleting assays further showed that when using
artificially constructed microtubule-binding repeats, two repeats had a weaker affinity for
microtubules than three repeats or even four repeats, which had the strongest affinity11.
Along with the NMR work, these study are not entirely consistent with the kinesin-1 data
or reported dynamic equilibriums of Tau where the 3RS, with one less microtubule
binding repeat, spends more time in the static state on the microtubule than the isoform
with four microtubule binding repeats24,47.
N-terminal acidic inserts may have an effect on the dynamic equilibrium of Tau.
Since the NMR work shows that more MTBRs alone correlates with a higher
affinity for the microtubule, additional features of the Tau molecules must be
contributing to its ability to switch between its static and diffusive states. One such
component may be the presence of the N-terminal acidic inserts. Most of the previous
research on Tau has compared the 3RS with 4RL isoforms. Despite the importance of the
work, there are multiple differences between the molecules that limit the ability to
attribute changes in Tau dynamics to any single region of the molecule (Figure 3). In
particular, 3RS has three microtubule binding repeats and no N-terminal acidic inserts
while 4RL has four microtubule inserts and two N-terminal acidic inserts21. It is,
therefore, not possible to determine whether it is the N-terminal inserts or the MTBRs
influencing the dynamics and functions of the Tau isoforms.
It is important to understand differences caused by these acidic inserts because
constructs with two inserts will likely have a longer projection above the microtubule that
could possibly recruit more PP1 and GSK3β for cargo delivery and signaling. The acidic
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inserts, however, may also change the equilibrium of static to diffusive Tau by stabilizing
the diffusive state and reducing the time a Tau is static with its PAD exposed for
signaling.
Differences between the six isoforms of Tau needs to be better understood.
The research performed here proposes to examine differences in the dynamic
equilibrium of Tau by comparing Tau isoforms with different N-terminal acidic insert
numbers but the same number of MTBRs. The results will contribute to understanding of
how the N-terminal acidic inserts may change Tau’s equilibrium and, therefore, its ability
to signal.
The following study will examine the difference between acidic inserts within 3repeat Tau molecules. By keeping the microtubule-binding repeat numbers constant, this
study will directly determine the role of the acidic inserts on Tau’s dynamic equilibrium
on the microtubule surface. The research will compare 3RL, with two N-terminal acidic
inserts, to 3RS, with no N-terminal acidic inserts. This study proposes that the N-terminal
acidic inserts have an effect on the equilibrium of Tau on the microtubule surface. This
study proposes that the isoform with two N-terminal acidic inserts will diffuse more often
and for longer than the isoform without the inserts because the additional negative charge
of the 3RL isoform is able to stabilize the dynamic state.
Previous methods of data analysis may not have been sensitive enough to capture all
events in single molecule assays.
The research presented here will examine the dynamic behavior of 3RS and 3RL.
Previous research was able to compare the 3RS and 4RL isoforms but the methods used
may not have been sensitive enough to capture short events or events that switched
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between states (Figure 8). The initial work was completed by hand-selecting and
characterizing events. In general, this means that very short events that were shorter than
0.5 s were too difficult to objectively characterize as static or diffusive and were,
therefore, discarded. Even with strict guidelines, some events were hard to confidently
categorize by eye as diffusive or static and were, therefore, not included. Finally, any
event that had both static and diffusive components, which is considered a switching
event, was discarded.
The research presented here developed a novel data analysis to address the
limitations of the previous methods. The research aims to take away the subjectivity of
hand-picking and characterizing events. In addition, the data was analyzed by running the
vectors of the events through a code designed specifically to be more sensitive to short
events, objectively threshold which events where static or diffusive, and categorize
events that switched between states.
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MATERIALS AND METHODS
Plasmid Purification and Protein Prep
Tau constructs were purified from a modified pET vector, the ampicillin-resistant
pET 3d, and transformed into BL21 competent cells (Aligent cat. 230255) that were
pemeabilized on ice with βME (Bio-Rad cat. 161-0710). 2-5 ng of plasmid DNA was
introduced to 100 µL of cells on ice and incubated for 30 minutes to allow the DNA to
flow into the cells. The cells were heat pulsed for 30 seconds at 42°C then placed on ice
for 2 minutes. Cells received 900 µL of S.O.C. recovery media (Invitrogen cat. 15544034, part 46-0821) and shook at 37°C, 225 rpm for 60 minutes. A range from 5-100 µL
of cells were then plated on pre-warmed LB agar (Fisher Scientific BP 9724-500) plates
with 50 µg/mL ampicillin salt (Sigma Aldrich A01566-5G) and incubated overnight at
37°C.
After 16 hours plates were removed from the incubator and one colony was
selected from a plate with sufficient growth to indicate a successful transformation, but
without satellite colonies or overcrowding. The colony was place in 250 mL of LB (USB
cat. 75852) with 0.1 mg/ml of ampicillin and rocked overnight at 37°C, 225 rpm. After
16 hours, the cloudy sample indicated growth and 10 mL were taken into 1 L of LB-amp
at 0.1 mg/mL. The culture shook at 37°C, 225 rpm until the OD measured at λ600 was
0.6, approximately three hours. The culture was then induced with 0.5 mM IPTG (Sigma
cat. I6758-5G) and continued incubating for five hours.
At the end of five hours, the 1 L culture was spun down in a Sorvall GS-3 rotor
(Thermo Fisher Scientific, Waltham, MA) for 20 min at 6,500 rpm. The supernatant was
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discarded and the pellet was saved at -80°C overnight. The pellet was thawed at room
temperature for 45 minutes then lysed in 40 mL of lysis buffer (3.3mL 10X BRB80 [800
mM PIPES pH 6.8 w/KOH, 10 mM EGTA, 10 mM MgSO4], 3.3mL 10X cellytic B, 10
mM BME, 26.6mL ddH2O, 0.2 mg/mL lysozyme, 20 µg/mL leupeptin, 1 µg/mL
Pepstatin A, 10 µg/ mL Aprotinin, 1 mM PMSF, 7500 U at 250 U/µl Benzonase) and
homogenized on ice until the pellet was completely broken up and the solution was
uniform.
The solution containing the Tau protein was then sonicated on ice to break open
the cells at a continuous pulse on for 30 seconds with 30 seconds or rest in between for 57 times until the solution was clear. The solution was spun in a SA600 (Thermo Fisher
Scientific, Waltham, MA) rotor for 20 minutes at 4°C at 15,000 rpm. The pellet was
discarded and the supernatant was placed in boiling water for 20 minutes. Most of the
proteins from the cell precipitated out and were spun down in the SA600 rotor for 20
minutes at 4°C at 15,000 rpm. Tau was in the supernatant and was filtered through a 0.22
µm filter. The salutation was then applied to a Q Sepharose Fast Flow column (Sigma
cat. Q1126-100mL) at 4°C at a rate of 0.5-0.8 mL/min. The flow-through containing Tau
was collected and stored overnight on ice at 4°C.
The flow-through from the Q Sepharose column was applied to an SP Sepharose
column (Sigma cat. S1799-100mL) at a rate of 0.5-0.8 mL/min. Tau sticks to the SP
column so the flow-through was discarded. The column was then washed with BRB80
until the OD read at λ280 was zero. Once the OD reached zero, 200 mM NaCl was
applied to the column to elute the Tau off the column in 1 mL fractions. The OD λ280
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was recorded for each third fraction to create an elution curve. Once the elution peaked
and fell back closer to zero, the salt was increased to 1 M NaCl and several fractions were
collected.
Every other fraction was run on an SDS-PAGE gel and stained with Coomassie
Blue stain (Figure 9A-B). Based on the samples on the gel, fractions containing Tau were
pooled and placed in dialysis tubing 12-14 kDa MW cut off (Spectrum Labs cat. 132 678)
and dialyzed in 2 L of 1x BRB80 overnight. After 16 hours, the dialysis tubing was
placed in 1 L 1x BRB80 and dialyzed an additional 5 hours. The samples were aliquoted
and flash frozen in liquid nitrogen to store long-term at -80°C. Tau concentrations were
tested by a bicinchoninic acid assay (BCA assay) (Thermo Scientific prod. 23225)
(Figure 9B).
Tau labeling with Alexa 488.
Tau constructs were labeled with Alexa-488 (Life Technologies cat. A10254) that
uses a cysteine-maleimide-fluor linkage system. Since the 3R-Tau only has one cysteine
residue in microtubule-binding repeat three, the second MTBR present in the protein
(Figure 3) the constructs were singly labeled. Tau was incubated at 10x its concentration
of DTT for two hours at room temperature to reduce disulfide bonds in the protein. The
sample was spun through Zeba desalting columns 7k molecular weight, 2 mL volume
(Thermo Scientific cat. 89889) that had been equilibrated with 1 mL of 1x BRB80 three
times. The flow-through was taken and incubated with 3x Alexa-488 10 mM in DMF for
two hours in the dark at room temperature. Tau-488 samples were then spun through the
same type of Zeba desalting columns equilibrated the same. The flow-through was
collected and aliquoted for single molecule assays and flash frozen in liquid nitrogen for
23

long-term storage at -80°C. Samples were run on a polyacrylamide gel to ensure no nonspecific labeling occurred and that all excess dye had been filtered out (Figure 9C-D).
The concentration of Tau-488 constructs was determined by BCA assay (Figure
9D). The efficiency of labeling was measured by
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where the

concentration of label was determined by absorbance at λ493, the absorbance of the
Alexa 488 dye, at different dilutions of the labeled protein. The concentration was then
determined by the formula M = (OD/extinction coefficient )*dilution factor using the Alexa 488
extinction coefficient.
In this study, the 3RS-Tau-488 construct stock concentration was at 92.28 µM
and labeled with 49.6% efficiency. 3RL-Tau-488 stock concentration was at 23.33 µM
and labeled at 97.8% efficiency.
Diffusion Assay: Tubulin Polymerization.
Tubulin purified from calf brains underwent a clarification spin at 350,000 x g at
4°C in a TLA 100 rotor in an ultracentrifuge for 20 minutes. The supernatant was
removed and polymerized in the presence of 1 mM GTP at 37°C for 20 minutes. A
sample of the supernatant was used to determine the OD at λ280 to find the tubulin
concentration. The polymerized microtubules were stabilized with 20 µM paclitaxel and
incubated at 37°C for at least 5 minutes.
Diffusion Assay: TIRF Assay
The dynamic behavior of Tau was determined by a total internal reflection
fluorescence assay (TIRF). Flow cells were constructed by adhering 0.005 mm plastic
shims (Artus plastic shims, 0.005-0.125m/m) to silanized cover slips coated with PEG.
24

All solutions were diluted in a motility buffer (97% 1x BRB80, oxygen scavengers [3.5
mg glucose, 27 ng catalase from bovine liver, 40 ng glucose oxidase from Aspergiuls
niger], 10 mM DTT). A stock concentration of microtubules was incubated at 1:3000
with the appropriate Tau construct at 37°C for 20 minutes. All reagents were prepared
fresh for imaging that day.
For imaging, anti-β III tubulin was introduced to flow cells and incubated for 5
minutes. Two washes of 0.5 mg/mL of BSA were flow-in to block spots without
antibodies bound on the flow cells and allowed to bind for 2 minutes each. Between 1.21.5 µM of microtubules, diluted from stock concentrations incubated with Tau, were then
flowed in and incubated for 12 minutes. Tau was flowed in at a 1:3000 ratio of the
microtubules, between 0.4-0.5 nM of Tau, and incubated for two minutes.
Slides were imaged with TIRF immediately on an inverted microscope (Eclipse
Ti-U, Nikon) with a 100_ plan apochromatic objective lens (1.49 NA) and auxiliary 1.5_
magnification. Microtubules were first found and imaged with a 532 nm argon laser with
an emission 605/70 band-pass filter. A 473 nm argon laser was then used to excite the
Tau constructs with an emission 525/50 band-pass filter. The videos were captured by an
XR/Turbo-Z camera (Stanford Photonics) with Piper Control software (v2.3.39) at a pixel
resolution of 93 nm. On the microtubule field, 50 images were taken at 10 frames/second
before immediately switching to image the Tau field for 1000 images at 10
frames/second.
Diffusion Assay: Data Analysis
Files from imaging were analyzed using ImageJ software,version 1.46r (National
Institutes of Health, Bethesda, MD). Tau events were first confirmed by generating
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kymographs, a two-dimensional representation of a movie, using the “multiple
kymograph” plugin in ImageJ (Figure 8). Microtubule tracks were hand selected using
the line tool and superimposed on the Tau fields to generate the kymographs (Figure
10A). Actual events were tracked using the MTrackJ plugin. Tau molecules were hand
selected and followed through successive frames using MTrackJ with a single frame step
between points (Figure 10B-C).
Data Analysis: MatLab
The spatial coordinates of the Tau events selected in the MTrackJ plugin were
imported into MATLAB version R2016b (MathWorks, Natick, MA). A custom program
was developed to distinguish between static and diffusive states for every event. The
program calculated displacement of Tau particles at each time interval of 0.1 s, the frame
rate during data collection, and the displacements were stored in a vector (Figure 10B-C).
A sliding window analysis was performed on this displacement vector with a sliding
window of size of 3 frames moving along the displacement vector.
The maximum displacement was then calculated for each window. When the
maximum displacement was less than 0.3 microns that region was classified as static and
when the maximum displacement was greater than 0.3 microns that region was classified
as diffusive. The threshold for a static versus diffusive molecule was based on the point
spread function of the fluor and minimum amount of movement able to be detected. The
size of the sliding window was optimized by analyzing simulated data. In this analysis,
only those tau molecules that had a time interval greater than or equal to 0.4 s were used.
From the sliding window analysis; the percentage of static and diffusive events, the
percentage of transitions between states, and the time spent in each state was determined.
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To calculate the Diffusion Coefficient (D) and alpha value for diffusive events the
mean squared displacements (MSD) were fit to the following equation (Figure 12):
Equation 1

α

x2 = 4Dt

where x2 is the MSD and t is the time interval. MSD was first calculated for individual
events using the following equation:
Equation 2
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Where j is the time interval, L is the number of values in the displacement vector and
𝑑𝑖, 𝑖 + 𝑗 is the displacement between time i and and i + j. In this way MSD was
calculated for each diffusive event. Then the MSD was averaged over all particles and fit
to the diffusion equation to calculate D and the alpha value. The alpha value is the
exponent of the time interval in Equation 1 and is a measure of the nature of the
movement of a diffusive Tau event. It describes the nature of the line in the MSD versus
time graph. If the alpha value is less than 1, the line is logarithmic and suggests a subdiffusive particle. If the value is equal to 1, the line will be linear and indicates a perfectly
diffusive molecule. Finally if the value is 2, the line will be exponential and suggests
directed motion.
Data Analysis: Statistics
The lifetimes of the static and diffusive events were plotted on cumulative
frequency plots using Graph Pad Prism version 7.0a (GraphPad Software, Inc. La Jolla,
CA). The cumulative frequency plots were analyzed with a single exponential decay and
the fit values, R2 values, were recorded as well as the dwell times, τ. The percentages of
static and diffusive events were plotted as bar graph in Graph Pad Prism. Standard
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deviations were calculated as:
Equation 3

standard deviation = √(p*q*100)

The percentages were compared by a two-tailed Fisher’s exact test with a confidence
interval of 95% through Graph Pad Prism. This statistical method allowed for comparison
between the percentage of 3RS and 3RL events in the static versus diffusive states to
determine statistical significance. The same process was repeated for the percentages of
switching events to determine if there was statistical significance between the 3RS and
3RL rates.
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RESULTS
Characterization of the 3RS and 3RL isoforms.
The expressed 3RS and 3RL isoforms were first characterized for purity. In the
protein preps, the predominant product is the Tau protein running near 37 kDa on the
SDS-PAGE gel. As seen in a representative gel of fractions from column elution (Figure
9A), the primary product is the 3RS protein that elutes cleanly in approximately 8-10
fractions. The concentrations of 3RS and 3RL were determined by a BCA assay run
against a known Tau standard (Figure 9B). The protein concentrations were then used to
determine the amount of Alexa-488 needed to incubate the protein with the dye at a 3X
concentration. The SDS-PAGE gels run after labeling were stained with Coommassie
Blue after imaging fluorescence on a UV light box (Figures 9C-D). Again the
predominant product that was labeled is the 37 kDa Tau protein. There is also not an
excess amount of dye from the labeling process as seen on the SDS-PAGE gel.
Concentrations were again determined by a BCA assay and the percentage of Alexa-488
labeling was determined using the known extinction coefficient of the Alexa-488 dye.
The resulting 3RS stock concentration was 92 µM, 49.6% labeled of which as labeled
with Alexa-488. 3RL had a final concentration of 23 µM and was 97.8% labeled with
Alexa-488.
3RS and 3RL are found more often in the static state than the diffusive state.
In the single-molecule diffusion assays, 3RS dynamics were measured in four
separate experiments and 3RL dynamics were measured in three separate experiments. In
each experiment data was collected from 1-2 flow cells per day and a total, across all
experiments, of 14 different Tau fields for 3RS and 20 different Tau fields for 3RL. Each
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field had at least 100 Tau molecules imaged over 100 seconds at 10 frames/second. In
total, 555 events of 3RS were analyzed and 2168 events of 3RL (Figure 11).
The analysis showed that 3RS was in the static state 63% of the time and in the
diffusive state 37% of the time. Similarly, 3RL was static 69% of the time and diffusive
31% of the time. The percentages of static Tau were not statistically significant between
the two isoforms with a P-value of 0.4556 at a 95% confidence interval of p < 0.05
(Figures 11 and 13).
3RS and 3RL have longer static dwell times than diffusive dwell times.
Both 3RS and 3RL Tau had longer static dwell times than diffusive dwell times.
Cumulative frequency plots were fit with a one-phase decay and the lifetime values were
recorded as the dwell times (Figure 11). 3RS had a static dwell time of 0.53 s compared
to its diffusive dwell time of 0.09 s. The static dwell time for 3RL at 0.55 s was six times
longer than its diffusive dwell time at 0.12 s. The R2 values, indicating the fit of the onephase decay to the data, were as follows: 0.9806 for 3RS-static, 0.9816 for 3RL-static,
0.9982 for 3RS-diffusive, and 0.9994 for 3RL-diffusive (Figure 11C).
3R-Tau is more likely to switch from the diffusive state into the static state.
The novel data analysis developed here was sensitive enough to account for Tau
events that switched from one state to the other. By using the sliding window analysis,
the rates were determined for events that switched from the static to diffusive state and
from diffusive to static state (Figures 12 and 13). Diffusive 3RS and 3RL constructs
switched from diffusive to static 25% and 28% of the time, respectively. Comparatively,
static 3RS molecules had a switching percentage from static to diffusive at a rate of 14%.
3RL static molecules also switched from static to diffusive at a rate of 14% (Figures 12
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and 13). These percentages were not statistically significant from each at a P-value of
0.8198 at a 95% confidence interval of p < 0.05.
3RS and 3RL Tau are diffusive with no directed motion.
The final parameters determined from the mean-squared displacement (MSD)
analysis were diffusion coefficients and alpha values for 3RS and 3RL. The diffusion
coefficients were 0.072 µm2/s for 3RS and 0.055 µm2/s for 3RL. The alpha values were
determined by plotting the MSD over time. The lines were linear, indicating an alpha
value near 1, indicative of purely diffusive molecules. The alpha values were 0.970 for
3RS and 1.055 for 3RL (Figure 14).
3RS and 3RL have much shorter dwell times than previously reported.
Previous work had shown that 3RS is static 62% of the time with a static dwell
times of 19.6 s and diffusive dwell times of 3.60 s (Figure 15)24. The current work found
3RS was static 63% of the time with a static dwell time of 0.53 s and diffusive dwell time
of 0.09 s. In order to understand the differences between the dwell times, the current data
analysis was run again on the 3RS and 3RL data sets using the same thresholds as stated
previously. Namely, any events less than 0.5 s (5 frames) were discarded. The results
showed that the dwell times were not drastically changed (Figure 15). 3RS under the new
parameters had a static dwell time of 0.63 s and a diffusive dwell time of 0.11 s. 3RL had
a static dwell time of 0.68 s and a diffusive dwell time of 0.13 s.
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DISCUSSION
3RS- and 3RL-Tau have similar dynamic equilibriums favoring the static state.
As shown in the results in Figures 11 and 13, both the 3RS and 3RL isoforms
favor the static state at a 2:1 ratio. This is consistent with previous results using a 1:3000
ratio of 3RS to tubulin where 3RS was found to be static 62% of the time24. This suggests
that 3-repeat Tau isoforms overall favor the static state two-thirds of the time on the
microtubule lattice.
The dwell times of 3RS and 3RL similarly showed a preference for the static
state. Both isoforms had a static dwell time around 0.5 s, five times their diffusive dwell
times of approximately 0.1 s (Figures 11 and 13). These results also provide an insight
into the length of time Tau may be on the microtubule to perform its various functions. In
general, 3-repeat Tau molecules had short dwell times that indicate rapid turnover of the
molecules on the microtubule surface. Previous work had found a similar relationship
where 3RS spends five times as long in the static state as the diffusive with dwell times
of 19.6 s to 3.60 s respectively24.
The novel data analysis method was more sensitive and captured many more short
events than previous methods.
The analysis method used here was more sensitive and was able to characterize
events that were not considered in the previous work (Figures 8 and 10). By using the
sliding window analysis, a greater number of shorter events that were less than 0.5 s were
captured. Events were also captured that either underwent a switching event or were not
used previously because they were not clearly static or diffusive. Previous events were
captured by hand-selecting Tau events directly from kymographs. In using kymographs,
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very short events were not recorded and events were it was unclear if the molecule was
diffusing were discarded.
To make sure that the dramatic differences in dwell times was not an artifact of
the novel data analysis used, the data was run through the analysis again using the same
thresholds as previous published. This meant any event that was les than 0.5 s was
discarded (Figure 15). The results showed that 3RS under the new parameters had a static
dwell time of 0.63 s and a diffusive dwell time of 0.11 s. 3RL had a static dwell time of
0.68 s and a diffusive dwell time of 0.13 s. These dwell times are still much shorter than
previously reported, suggesting that the new data analysis method was indeed able to
capture many events around 0.5 s that would not have been detected using previous
methods of analysis.
In general, many of the Tau events were close to 0.5 s. This suggests that many
Tau events are relatively short. The previous data analysis characterized events by eye as
either diffusive or static. As seen in Figure 8, even with strict parameters; this can be
challenging because of noise in the data collection or because these events have motion
but may not be enough to categorize as diffusive or static. This data analysis used the
spatial coordinates of each event and used MATLAB codes to determine the amount the
event moved between frames. The subjectivity, therefore, was eliminated and events that
had noise could be clearly categorized.
3R-Tau is more likely to switch from the diffusive state into the static state.
Since this study used a novel analysis method, more information was captured
including the rates of switching between static and diffusive events. Previously events
like the one identified in the top kymograph of Figure 8, where a Tau switched between
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states, were observed on kymographs but not quantitated. Again these results favor the
static state for both 3RS and 3RL. Both constructs were approximately twice as likely to
switch from the diffusive state to the static state than to begin diffusing while in the static
state (Figure 12). 3RS and 3RL switched favored a switch from the diffusive to the static
state 25% and 28% of the time, respectively. The 3R-Tau both switched from static to
diffusive 14%.
These results suggest that the 3-repeat Tau may be more stable in the static state
or that it is an electrostatically more favorable conformation. In addition, the results may
indicate that it is more favorable for the protein to shift from its conformation in the
diffusive state into the static state. Since there is no known structure of Tau, more
information is needed to understand why 3R-Tau favors the static state. A potential
model for further study is that 3-repeat Tau lands on the microtubule and diffuses until it
finds a suitable location. Since Tau has known signaling and other roles in the axons, it is
possible Tau can land and search in the diffusive state for the appropriate location before
binding.
3RS and 3RL-Tau have similar dynamic equilibriums.
This study compared 3RS and 3RL isoforms that only differ in the number of Nterminal acidic inserts. Since the percentages of static and diffusive events were not
significantly different and the dwell times were comparable, these results suggest that
there is no effect of the acidic inserts on Tau’s equilibrium. The presence of two
additional acidic inserts in 3RL did not significantly change its behavior on the
microtubule compared to the 3RS as expected. The N-terminal acidic inserts may,
therefore, not have a role in the dynamics of Tau but have a greater effect on its signaling
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or microtubule-spacing functions15,14.
Tau is a purely diffusive molecule, with no directed motion or direction bias.
The diffusion coefficients of both 3RS and 3RL show that Tau is a diffusive
molecule over distances with diffusion coefficients (D) of 0.072 µm2/s and 0.055 µm2/s,
respectively (Figure 14). These D suggest that Tau is diffusing over a relatively large
space each time. For comparison, the diameter of an average human microtubule is 20
nm. Since the diffusion coefficients were 72 nm2/s and 55 nm2/s, this indicates a pretty
diffusive molecule. These results are smaller than the previously reported diffusion
coefficients of 3RS at 0.18 µm2/s24. Since the data reported here was more sensitive to
shorter diffusive events, it is likely that the diffusion coefficient reflected more short
events captured that had less time to diffuse.
The alpha values for the 3-repeat isoforms were also calculated at 0.97 for 3RS
and 1.06 for 3RL (Figure 14). The alpha value is determined by plotting the MSD over
time. As seen in Figure 14, the plot of the line is linear with R2 values of 0.9446 for 3RS
and 0.9511 for 3RL, indicating a good fit to the line. The alpha values of 0.97 and 1.06
respectively are close to the alpha value of 1 indicating a purely diffusive molecule with
no directed motion. Taken together, the alpha values and diffusion coefficients suggest
that Tau is purely diffusive over distance.
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FUTURE DIRECTIONS
Evaluating Isoform Specific Differences
The results of this research show that there is not a significant difference in the
dynamic behavior of the 3RS and 3RL isoforms of Tau on the microtubule lattice. The
next step is to use the novel data analysis methods discussed here to assess the dynamics
of the remaining four isoforms. Since 3RS and 3RL had statistically similar dynamics on
the microtubule, the 3RM is proposed to also favor the static state at a 2:1 rate. 3RM is
additionally expected to have longer static dwell times than diffusive dwell times and
switch from the diffusive state into the static state twice as often as switching from static
to diffusive states.
The 4-repeat isoforms of Tau will likely have different dynamics than the 3-repeat
isoforms. Based on previous work comparing 3RS and 4RL dynamics24, the 4-repeat
isoforms are proposed to have a 1:1 equilibrium between the static and diffusive state.
The 4-repeat isoforms are proposed to similarly have longer diffusive dwell times than
the 3-repeat Tau and shorter static dwell times. The individual 4-repeat isoforms are not
expected to have statistically significant differences. These results would be similar to the
3-repeat work discussed above where the N-terminal acidic inserts alone do not have an
effect on the dynamic equilibrium of Tau. Since the 4-repeat isoforms have more
microtubule-binding repeats to interact with the tubulin of the microtubule, it is necessary
to evaluate the dynamics of those isoforms to know if there is any effect of the Nterminal acidic inserts and to further understand why the 4RL isoform was more diffusive
than 3RS in the previous work.
Further work is needed to characterize 3R-Tau’s behavior on the microtubule.
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Since 3-repeat Tau is known to form multi-Tau complexes24, it is possible that the
static state was longer and more frequent because multi-Tau complexes were being
observed. A brightness analysis was not performed as part of the experiments presented
in the current work. This assay is necessary to run in the future determine if the events
observed were single or multiple molecules. In addition, binding assay could be run to
determine the affinity and cooperativity of Tau for binding on the microtubule.
The analysis was stringent in the sense that any Tau event where a molecule
became diffusive, static, or seemingly disappeared but the entire event still went on was
discarded. For example, if a static Tau event was being measured through multiple
frames and in one frame part of the molecule began diffusing away and the rest of the
event was still static, it was assumed that there were actually at least two molecules being
imaged and the entire event was not recorded. Further analysis is needed to determine the
ability of 3RS and 3RL to form multi-Tau complexes and to look at the dwell times of
complexes of Tau.
Since the dwell times were similar in 3RS and 3RL, it is possible that they have
the same numbers of multi-Tau complexes. The rates of multi-Tau complexes also need
to be studied on the remaining four isoforms; 3RM, 4RS, 4RM, and 4RL. It would,
furthermore, be important to see if some isoforms are more often found as multi-Tau
complexes and how that effects their transition into the disease state.
Isoform Differences on Kinesin-1 motility and signaling
Since there are not significantly differences between the 3RS and 3RL-Tau
molecules, it would be interesting to look at known and proposed roles of Tau in axons to
determine function-specific differences of these two isoforms. One such study would be
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the motility of kinesin-1 in the presence of 3RS and 3RL to determine if the Tau isoforms
inhibit kinesin-1 runs different in any significant manner. Since the dynamic equilibriums
of 3RS and 3RL are similar, they may inhibit kinesin-1 similarly. Conversely, the
additional acidic inserts in 3RL may impact the way the molecule interacts with kinesin-1
and show very different inhibition of the motor protein. It would, therefore, be interesting
to observe kinesin-1 in single molecule motility assays, similar to those performed
before47,58, in the presence of 3RS or 3RL.
Further work could additionally look at differences in signaling between the 3RS
and 3RL isoforms. The initial work on the phosphatase-activating domain of Tau used
4RL-Tau15. It would, therefore, be interesting to see if the two added N-terminal inserts
effect the signaling capabilities of Tau. The PAD is the region right before the acidic
inserts begin. The presence of one or two acidic inserts could, therefore, project the PAD
further above the microtubule and modulate the Tau’s ability to signal. These N-terminal
acidic inserts may have an effect on recruiting kinases to initiate signaling for cargo
delivery and other functions. One way to see the effect of the inserts on signaling would
be to express different isoforms of Tau in cells and looks at the levels of phosphorylation
on kinesin-1. This would indirectly show a change in signaling and recruitment of
GSK3β and PP1 in the presence of different isoforms.
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CONCLUSION
Since there were not any statistical differences in the dynamic equilibriums of
3RS and 3RL, it is possible that there are functional differences based on the N-terminal
acidic inserts. Further studies are needed to determine if the isoforms have
complementary roles in signaling, microtubule spacing, and kinesin-1 inhibition. In
addition, more work is needed to compare how all six constructs function and to begin
understanding why there are six isoforms in the adult brain. Finally, these studies could
be used to determine how Tau develops into the pathologies found in neurodegenerative
diseases and potential therapeutic targets.
The research described here is an important first step to answer many of these
questions and to understanding the Tau protein. First, the novel data analysis tools
developed here provided a more detailed and thorough characterization of the 3RS and
3RL Tau proteins. These methods can be applied to other single molecule studies
assessing the dynamics of Tau and other MAPs. Secondly, this study looked at two Tau
isoforms that were previously not characterized relative to each other. By examining 3repeat isoforms, the work here begins to understand the role of the N-terminal acidic
inserts on the dynamics of Tau.
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